Deep Genomics

Q: When was Deep Genomics last fund created?

Deep Genomics last fund was created/launched in 2014-11-10.

General contacts

Investor type

PE / VC

Founded

2015

AUM

$236 M

Location

Toronto, Ontario, Canada

Investment Ticket

$10-50 m

Investment Stage

Seed Series A Series B Late Stage (Series C+)

Region of investment

North America Europe

Investor profile last updated: 16 August, 2026

Profile

Deep Genomics is an AI-driven genetic medicines platform company based in Toronto, Ontario, Canada, founded in 2014 by Brendan Frey and Hui Yuan Xiong. The company employs around 100 people and focuses on solving complex molecular design and target biology problems using its Biological Foundation Model (BioFM) Platform. This platform integrates AI model development, lab-in-the-loop workflows, and fit-for-purpose training datasets to accelerate drug discovery.

Deep Genomics specializes in drug discovery, particularly in RNA biology, using AI to identify novel targets and therapeutic candidates for genetic conditions. The company operates at the intersection of biotechnology and artificial intelligence, focusing on sectors such as drug discovery, biotechnology, and life sciences. It has raised $238 million in funding from investors like Khosla Ventures, True Ventures, and SoftBank Vision Fund.

Notable investments include collaborations with companies like Geneoscopy, CureVac, and Stoke Therapeutics, which are involved in genetic therapy and RNA-based treatments. These partnerships highlight Deep Genomics' commitment to advancing the field of genetic medicine through innovative AI-driven solutions.

Industry

Life Sciences Biotechnology Healthcare Services Software AI Technology HealthTech Machine Learning (ML) Consumer Services (B2C)

Deep Genomics Funds

Name	Type	Industry	Stage	Region	Size	AUM	Launch date
Deep Genomics funding rounds	Venture Capital (VC)	Consumer Services (B2C) Healthcare Services AI Technology HealthTech Machine Learning (ML)	Seed Series A	North America Europe	$5-10 m	$236 M	November 2014

Contacts

Name

Title

Social Networks

Brian O'Callaghan Chief Executive Officer

Chief Executive Officer

b•••@•••

Brendan Frey, Ph.D. Chief Innovation Officer and Founder

Chief Innovation Officer and Founder

b•••@•••

Upgrade to see contacts

EWwt2ADsiSQLZx7h EWwt2ADsiSQLZx7h

EWwt2ADsiSQLZx7h

[email protected]

EWwt2ADsiSQLZx7h EWwt2ADsiSQLZx7h

EWwt2ADsiSQLZx7h

[email protected]

EWwt2ADsiSQLZx7h EWwt2ADsiSQLZx7h

EWwt2ADsiSQLZx7h

[email protected]

Investment-team contacts for Deep Genomics — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.

Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Deep Genomics

Is Deep Genomics a venture capital or private equity firm?

Deep Genomics is a venture capital and private equity firm. It backs companies at Seed, Series A, Series B and Late Stage (Series C+), writing tickets of $10-50 m.

Where is Deep Genomics located?

Deep Genomics is located in Toronto, Ontario, Canada.

When was Deep Genomics founded?

Deep Genomics was founded in 2015.

What sectors and industries does Deep Genomics invest in?

Deep Genomics invests in companies and startups in Life Sciences, Biotechnology, Healthcare Services, Software, AI, Technology, HealthTech, Machine Learning (ML), Consumer Services (B2C).

What is Deep Genomics geographical focus of investments?

Deep Genomics invests in companies and startups in North America, Europe.

At what stages of companies and startups does Deep Genomics typically invest in?

Deep Genomics invests in companies and startups at Seed, Series A, Series B, Late Stage (Series C+).

What is the usual amount of Deep Genomics investment?

Deep Genomics usually invests $10-50 m on average.

What is the amount of assets of under management (AUM) for Deep Genomics?

Deep Genomics has around $236m assets under management.

When was Deep Genomics last fund created?

Deep Genomics last fund was created/launched in 2014-11-10

What are the contacts of Deep Genomics?

Deep Genomics can be reached through its website deepgenomics.com, its LinkedIn page and its X account. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Deep Genomics — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

Can I access Deep Genomics data via API or MCP?

Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Deep Genomics directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.

When was the Deep Genomics profile last updated?

Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 16 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.